|
1
|
Lum LHW and Tambyah PA: Outbreak of
COVID-19 - an urgent need for good science to silence our fears?
Singapore Med J. 61:55–57. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
World Health Organization: WHO Coronavirus
Disease (COVID-19) Dashboard. https://covid19.who.int/. Accessed August 30,
2020.
|
|
3
|
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong
Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al: Early Transmission
Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.
N Engl J Med. 382:1199–1207. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tsatsakis A, Calina D, Falzone L, Petrakis
D, Mitrut R, Siokas V, Pennisi M, Lanza G, Libra M, Doukas SG, et
al: SARS-CoV-2 pathophysiology and its clinical implications: An
integrative overview of the pharmacotherapeutic management of
COVID-19. Food Chem Toxicol. 146(111769)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Nitulescu GM, Paunescu H, Moschos SA,
Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK,
Drakoulis N and Tsatsakis A: Comprehensive analysis of drugs to
treat SARS CoV 2 infection: Mechanistic insights into current COVID
19 therapies (Review). Int J Mol Med. 46:467–488. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ruscitti P, Berardicurti O, Iagnocco A and
Giacomelli R: Cytokine storm syndrome in severe COVID-19. Autoimmun
Rev. 19(102562)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Napp LC and Bauersachs J: Extracorporeal
Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm
Syndrome. Shock. 54:700–701. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang
Q, Luo Y, Chan JF, Sahi V, Figueroa A, et al: Potent neutralizing
antibodies against multiple epitopes on SARS-CoV-2 spike. Nature.
584:450–456. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Satarker S and Nampoothiri M: Structural
Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. Arch
Med Res. 51:482–491. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen N, Zhou M, Dong X, Qu J, Gong F, Han
Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in
Wuhan, China: A descriptive study. Lancet. 395:507–513.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J,
Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical Characteristics
of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected
Pneumonia in Wuhan, China. JAMA. 323:1061–1069. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu
Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet.
395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wan Y, Shang J, Graham R, Baric RS and Li
F: Receptor Recognition by the Novel Coronavirus from Wuhan: An
Analysis Based on Decade-Long Structural Studies of SARS
Coronavirus. J Virol. 94:e00127–e20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q,
Chang J, Hong C, Zhou Y, Wang D, et al: Neurologic Manifestations
of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan,
China. JAMA Neurol. 77:683–690. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Xu X, Chen P, Wang J, Feng J, Zhou H, Li
X, Zhong W and Hao P: Evolution of the novel coronavirus from the
ongoing Wuhan outbreak and modeling of its spike protein for risk
of human transmission. Sci China Life Sci. 63:457–460.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mangalmurti N and Hunter CA: Cytokine
Storms: Understanding COVID-19. Immunity. 53:19–25. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lin SH, Zhao YS, Zhou DX, Zhou FC and Xu
F: Coronavirus disease 2019 (COVID-19): Cytokine storms,
hyper-inflammatory phenotypes, and acute respiratory distress
syndrome. Genes Dis. 7:520–527. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xu J, Zhong S, Liu J, Li L, Li Y, Wu X, Li
Z, Deng P, Zhang J, Zhong N, et al: Detection of severe acute
respiratory syndrome coronavirus in the brain: Potential role of
the chemokine mig in pathogenesis. Clin Infect Dis. 41:1089–1096.
2005.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Wong CK, Lam CW, Wu AK, Ip WK, Lee NL,
Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, et al: Plasma
inflammatory cytokines and chemokines in severe acute respiratory
syndrome. Clin Exp Immunol. 136:95–103. 2004.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mahallawi WH, Khabour OF, Zhang Q,
Makhdoum HM and Suliman BA: MERS-CoV infection in humans is
associated with a pro-inflammatory Th1 and Th17 cytokine profile.
Cytokine. 104:8–13. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Neurath MF: COVID-19 and immunomodulation
in IBD. Gut. 69:1335–1342. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sapan HB, Paturusi I, Jusuf I, Patellongi
I, Massi MN, Pusponegoro AD, Arief SK, Labeda I, Islam AA, Rendy L,
et al: Pattern of cytokine (IL-6 and IL-10) level as inflammation
and anti-inflammation mediator of multiple organ dysfunction
syndrome (MODS) in polytrauma. Int J Burns Trauma. 6:37–43.
2016.PubMed/NCBI
|
|
23
|
Kang YJ, Jeung IC, Park A, Park YJ, Jung
H, Kim TD, Lee HG, Choi I and Yoon SR: An increased level of IL-6
suppresses NK cell activity in peritoneal fluid of patients with
endometriosis via regulation of SHP-2 expression. Hum Reprod.
29:2176–2189. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang C, Fei D, Li X, Zhao M and Yu K: IL-6
may be a good biomarker for earlier detection of COVID-19
progression. Intensive Care Med. 46:1475–1476. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Crisafulli S, Isgrò V, La Corte L, Atzeni
F and Trifirò G: Potential Role of Anti-interleukin (IL)-6 Drugs in
the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.
BioDrugs. 34:415–422. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Velasco Puyo P, Moreno L, Diaz de Heredia
C, Riviere JG and Soler Palacin P: Tocilizumab in a child with
acute lymphoblastic leukaemia and COVID-19-related cytokine release
syndrome. An Pediatr (Engl Ed). 93:132–133. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Qian S, An J, Qi F, Ye L, Chen Q, Liu X,
Xie L and Li G: Tocilizumab exerts anti-inflammatory activity in
six critically ill COVID-19 patients: A retrospective analysis. Ann
Transl Med. 8(881)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tanaka T, Narazaki M and Kishimoto T:
Immunotherapeutic implications of IL-6 blockade for cytokine storm.
Immunotherapy. 8:959–970. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Le RQ, Li L, Yuan W, Shord SS, Nie L,
Habtemariam BA, Przepiorka D, Farrell AT and Pazdur R: FDA Approval
Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T
Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Oncologist. 23:943–947. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chen H, Wang F, Zhang P, Zhang Y, Chen Y,
Fan X, Cao X, Liu J, Yang Y, Wang B, et al: Management of cytokine
release syndrome related to CAR-T cell therapy. Front Med.
13:610–617. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Faguer S, Vergez F, Peres M, Ferrandiz I,
Casemayou A, Belliere J, Cointault O, Lavayssiere L, Nogier MB,
Prevot G, et al: Tocilizumab added to conventional therapy reverses
both the cytokine profile and CD8+Granzyme+
T-cells/NK cells expansion in refractory hemophagocytic
lymphohistiocytosis. Hematol Oncol. 34:55–57. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
32
|
Luo P, Liu Y, Qiu L, Liu X, Liu D and Li
J: Tocilizumab treatment in COVID-19: A single center experience. J
Med Virol. 92:814–818. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Xu X, Han M, Li T, Sun W, Wang D, Fu B,
Zhou Y, Zheng X, Yang Y, Li X, et al: Effective treatment of severe
COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA.
117:10970–10975. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Carey B and Trapnell BC: The molecular
basis of pulmonary alveolar proteinosis. Clin Immunol. 135:223–235.
2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sever-Chroneos Z, Murthy A, Davis J,
Florence JM, Kurdowska A, Krupa A, Tichelaar JW, White MR,
Hartshorn KL, Kobzik L, et al: GM-CSF modulates pulmonary
resistance to influenza A infection. Antiviral Res. 92:319–328.
2011.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Damiani G, McCormick TS, Leal LO and
Ghannoum MA: Recombinant human granulocyte macrophage-colony
stimulating factor expressed in yeast (sargramostim): A potential
ally to combat serious infections. Clin Immunol.
210(108292)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Li SF, Gong MJ, Zhao FR, Shao JJ, Xie YL,
Zhang YG and Chang HY: Type I Interferons: Distinct Biological
Activities and Current Applications for Viral Infection. Cell
Physiol Biochem. 51:2377–2396. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
González-Navajas JM, Lee J, David M and
Raz E: Immunomodulatory functions of type I interferons. Nat Rev
Immunol. 12:125–135. 2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song
P, Qiu F, Wang X, Zou X, Wan D, et al: Retrospective Multicenter
Cohort Study Shows Early Interferon Therapy Is Associated with
Favorable Clinical Responses in COVID-19 Patients. Cell Host
Microbe. 28:455–464.e2. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Chu H, Chan JF, Wang Y, Yuen TT, Chai Y,
Hou Y, Shuai H, Yang D, Hu B, Huang X, et al: Comparative
replication and immune activation profiles of SARS-CoV-2 and
SARS-CoV in human lungs: An ex vivo study with implications for the
pathogenesis of COVID-19. Clin Infect Dis. 71:1400–1409.
2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
O'Brien TR, Thomas DL, Jackson SS,
Prokunina-Olsson L, Donnelly RP and Hartmann R: Weak Induction of
Interferon Expression by SARS-CoV-2 Supports Clinical Trials of
Interferon Lambda to Treat Early COVID-19. Clin Infect Dis.
71:1410–1412. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Naji A, Eitoku M, Favier B, Deschaseaux F,
Rouas-Freiss N and Suganuma N: Biological functions of mesenchymal
stem cells and clinical implications. Cell Mol Life Sci.
76:3323–3348. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Enciso N, Avedillo L, Fermín ML, Fragío C
and Tejero C: Regenerative potential of allogeneic adipose
tissue-derived mesenchymal cells in canine cutaneous wounds. Acta
Vet Scand. 62(13)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wang X, Wang H, Lu J, Feng Z, Liu Z, Song
H, Wang H, Zhou Y and Xu J: Erythropoietin-Modified Mesenchymal
Stem Cells Enhance Anti-fibrosis Efficacy in Mouse Liver Fibrosis
Model. Tissue Eng Regen Med. 17:683–693. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Baharlou R, Rashidi N, Ahmadi-Vasmehjani
A, Khoubyari M, Sheikh M and Erfanian S: Immunomodulatory Effects
of Human Adipose Tissue-derived Mesenchymal Stem Cells on T Cell
Subsets in Patients with Rheumatoid Arthritis. Iran J Allergy
Asthma Immunol. 18:114–119. 2019.PubMed/NCBI
|
|
46
|
Corcione A, Benvenuto F, Ferretti E,
Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi
GL, Pistoia V, et al: Human mesenchymal stem cells modulate B-cell
functions. Blood. 107:367–372. 2006.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Luz-Crawford P, Kurte M, Bravo-Alegría J,
Contreras R, Nova-Lamperti E, Tejedor G, Noël D, Jorgensen C,
Figueroa F, Djouad F, et al: Mesenchymal stem cells generate a
CD4+CD25+Foxp3+ regulatory T cell
population during the differentiation process of Th1 and Th17
cells. Stem Cell Res Ther. 4(65)2013.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Gao F, Chiu SM, Motan DA, Zhang Z, Chen L,
Ji HL, Tse HF, Fu QL and Lian Q: Mesenchymal stem cells and
immunomodulation: Current status and future prospects. Cell Death
Dis. 7(e2062)2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Elgaz S, Kuçi Z, Kuçi S, Bönig H and Bader
P: Clinical Use of Mesenchymal Stromal Cells in the Treatment of
Acute Graft-versus-Host Disease. Transfus Med Hemother. 46:27–34.
2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Kamal MM and Kassem DH: Therapeutic
Potential of Wharton's Jelly Mesenchymal Stem Cells for Diabetes:
Achievements and Challenges. Front Cell Dev Biol.
8(16)2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Yang JH, Liu FX, Wang JH, Cheng M, Wang SF
and Xu DH: Mesenchymal stem cells and mesenchymal stem cell-derived
extracellular vesicles: Potential roles in rheumatic diseases.
World J Stem Cells. 12:688–705. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Radmanesh F, Mahmoudi M, Yazdanpanah E,
Keyvani V, Kia N, Nikpoor AR, Zafari P and Esmaeili SA: The
immunomodulatory effects of mesenchymal stromal cell-based therapy
in human and animal models of systemic lupus erythematosus. IUBMB
Life. 72:2366–2381. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Fu Y, Ni J, Chen J, Ma G, Zhao M, Zhu S,
Shi T, Zhu J, Huang Z, Zhang J, et al: Dual-Functionalized MSCs
that Express CX3CR1 and IL-25 Exhibit Enhanced Therapeutic Effects
on Inflammatory Bowel Disease. Mol Ther. 28:1214–1228.
2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Regmi S, Pathak S, Kim JO, Yong CS and
Jeong JH: Mesenchymal stem cell therapy for the treatment of
inflammatory diseases: Challenges, opportunities, and future
perspectives. Eur J Cell Biol. 98(151041)2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wang XY: MSCs transplantation may be a
potential therapeutic strategy for COVID-19 treatment. Eur Rev Med
Pharmacol Sci. 24:4537–4538. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Karaöz E and Tepeköy F: Differentiation
Potential and Tumorigenic Risk of Rat Bone Marrow Stem Cells Are
Affected By Long-Term In Vitro Expansion. Turk J Haematol.
36:255–265. 2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Shao C, Tian G, Huang Y, Liang W, Zheng H,
Wei J, Wei C, Yang C, Wang H and Zeng W: Thymosin
alpha-1-transformed Bifidobacterium promotes T cell proliferation
and maturation in mice by oral administration. Int Immunopharmacol.
15:646–653. 2013.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Hsia J, Sarin N, Oliver JH and Goldstein
AL: Aspirin and thymosin increase interleukin-2 and
interferon-gamma production by human peripheral blood lymphocytes.
Immunopharmacology. 17:167–173. 1989.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Wu X, Jia J and You H: Thymosin alpha-1
treatment in chronic hepatitis B. Expert Opin Biol Ther. 15 (Suppl
1):S129–S132. 2015.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Goldstein AL, Zatz MM, Low TL and Jacobs
R: Potential role of thymosin in the treatment of autoimmune
diseases. Ann N Y Acad Sci. 377 (1 Myasthenia Gr):486–495.
1981.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Ioannou K, Samara P, Livaniou E,
Derhovanessian E and Tsitsilonis OE: Prothymosin alpha: A
ubiquitous polypeptide with potential use in cancer diagnosis and
therapy. Cancer Immunol Immunother. 61:599–614. 2012.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Xu Z, Shi L, Wang Y, Zhang J, Huang L,
Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al: Pathological findings
of COVID-19 associated with acute respiratory distress syndrome.
Lancet Respir Med. 8:420–422. 2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Wand S, Klages M, Kirbach C, Warszawska J,
Meybohm P, Zacharowski K and Koch A: IgM-Enriched Immunoglobulin
Attenuates Systemic Endotoxin Activity in Early Severe Sepsis: A
Before-After Cohort Study. PLoS One. 11(e0160907)2016.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Alejandria MM, Lansang MA, Dans LF and
Mantaring JB III: Intravenous immunoglobulin for treating sepsis,
severe sepsis and septic shock. Cochrane Database Syst Rev.
2013(CD001090)2013.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Cao W, Liu X, Bai T, Fan H, Hong K, Song
H, Han Y, Lin L, Ruan L and Li T: High-Dose Intravenous
Immunoglobulin as a Therapeutic Option for Deteriorating Patients
With Coronavirus Disease 2019. Open Forum Infect Dis.
7(ofaa102)2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Stegmayr B, Ramlow W and Balogun RA:
Beyond dialysis: Current and emerging blood purification
techniques. Semin Dial. 25:207–213. 2012.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Luo S, Yang L, Wang C, Liu C and Li D:
Clinical observation of 6 severe COVID-19 patients treated with
plasma exchange or tocilizumab. Zhejiang Da Xue Xue Bao Yi Xue Ban.
49:227–231. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
68
|
Zuccari S, Damiani E, Domizi R, Scorcella
C, D'Arezzo M, Carsetti A, Pantanetti S, Vannicola S, Casarotta E,
Ranghino A, et al: Changes in Cytokines, Haemodynamics and
Microcirculation in Patients with Sepsis/Septic Shock Undergoing
Continuous Renal Replacement Therapy and Blood Purification with
CytoSorb. Blood Purif. 49:107–113. 2020.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Jiménez-Brítez G, Ruiz P and Soler X:
Tocilizumab plus glucocorticoids in severe and critically COVID-19
patients. A single center experience. Med Clin (Barc). 155:410–411.
2020.PubMed/NCBI View Article : Google Scholar : (In En,
Spanish).
|
|
70
|
Lockey RF and Hudey SN: Coronavirus
disease 2019-associated urticaria with angioedema in a morbidly
obese man successfully treated with glucocorticoids. Ann Allergy
Asthma Immunol. 125:359–360. 2020.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Zhao R, Wang H, Wang X and Feng F: Steroid
therapy and the risk of osteonecrosis in SARS patients: A
dose-response meta-analysis. Osteoporos Int. 28:1027–1034.
2017.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Zhou Y, Vedantham P, Lu K, Agudelo J,
Carrion R Jr, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH,
Renslo AR, et al: Protease inhibitors targeting coronavirus and
filovirus entry. Antiviral Res. 116:76–84. 2015.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Hoffmann M, Kleine-Weber H, Schroeder S,
Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, et al: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2
and Is Blocked by a Clinically Proven Protease Inhibitor. Cell.
181:271–280.e8. 2020.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Ramsey ML, Nuttall J and Hart PA: TACTIC
Investigative Team. A phase 1/2 trial to evaluate the
pharmacokinetics, safety, and efficacy of NI-03 in patients with
chronic pancreatitis: Study protocol for a randomized controlled
trial on the assessment of camostat treatment in chronic
pancreatitis (TACTIC). Trials. 20(501)2019.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Hong X, Xiong J, Feng Z and Shi Y:
Extracorporeal membrane oxygenation (ECMO): Does it have a role in
the treatment of severe COVID-19? Int J Infect Dis. 94:78–80.
2020.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Ramanathan K, Antognini D, Combes A, Paden
M, Zakhary B, Ogino M, MacLaren G, Brodie D and Shekar K: Planning
and provision of ECMO services for severe ARDS during the COVID-19
pandemic and other outbreaks of emerging infectious diseases.
Lancet Respir Med. 8:518–526. 2020.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Cho HJ, Heinsar S, Jeong IS, Shekar K, Li
Bassi G, Jung JS, Suen JY and Fraser JF: ECMO use in COVID-19:
Lessons from past respiratory virus outbreaks-a narrative review.
Crit Care. 24(301)2020.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Atluri S, Manchikanti L and Hirsch JA:
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a
Therapeutic Strategy in Managing Critically Ill COVID-19 Patients:
The Case for Compassionate Use. Pain Physician. 23:E71–E83.
2020.PubMed/NCBI
|
|
79
|
Tovar I, Guerrero R, López-Peñalver JJ,
Expósito J and Ruiz de Almodóvar JM: Rationale for the Use of
Radiation-Activated Mesenchymal Stromal/Stem Cells in Acute
Respiratory Distress Syndrome. Cells. 9(E2015)2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Kavianpour M, Saleh M and Verdi J: The
role of mesenchymal stromal cells in immune modulation of COVID-19:
Focus on cytokine storm. Stem Cell Res Ther. 11(404)2020.PubMed/NCBI View Article : Google Scholar
|
